Financial Enhancement Group LLC Coherus Bio Sciences, Inc. Transaction History
Financial Enhancement Group LLC
- $610 Million
- Q2 2024
Shares
2 transactions
Others Institutions Holding CHRS
# of Institutions
143Shares Held
82.7MCall Options Held
79.1KPut Options Held
100K-
Black Rock Inc. New York, NY11.8MShares$12.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.6MShares$11 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY10.4MShares$10.8 Million0.53% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U05.82MShares$6.05 Million0.05% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$3.16 Million0.3% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $80.8M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...